Artificial intelligence is rapidly transforming CRISPR genome editing, making it faster, safer, and more precise. From designing guide RNAs to engineering novel enzymes, AI is streamlining workflows ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

A year after Baby KJ became the first person to receive a personalized CRISPR base-editing therapy for a lethal genetic disorder, he is thriving and has avoided a liver transplant. His case, enabled ...

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Künzel, Associate Director in the Functional Genomics department at AstraZeneca, about the application of arrayed ...

Last August, KJ Muldoon was born with a potentially fatal genetic disorder. Just six months later, he received a Crispr treatment designed just for him. Muldoon has a rare disorder known as CPS1 ...

Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive enzymes towards invading bacteriophages that express ...

The United Nations predicts that there will be an additional 2.2 billion people on the planet by 2050. To help feed the growing population, the food industry must overcome several critical challenges, ...

Labroots invites you to the 8th Annual CRISPR Virtual Event Series 2025, taking place on October 22nd, 2025! This event will explore the expanding frontier of CRISPR technology, with sessions covering ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...